17-1589-42
antibody from Invitrogen Antibodies
Targeting: KIR2DL1
47.11, CD158A, cl-42, nkat1, p58.1
Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 17-1589-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD158a/h/g Monoclonal Antibody (HP-MA4), APC, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The monoclonal antibody HP-MA4 recognizes several CD158 proteins, also known as KIR2D, specifically KIR2DL1 (CD158a), KIR2DS1 (CD158h), KIR2DS3, and KIR2DS5 (CD158g). It does not recognize KIR2DL2 (CD158b1), KIR2DS2 (CD158j), KIR2DL4 (CD158d) or KIR2DS4 (CD158i) and crossreactivity to KIR2DL3 (CD158b2) and KIR2DL5 (CD158f) are unknown. CD158 proteins are members of the killer cell immunoglobulin-like receptors (KIR) family of transmembrane glycoproteins that are expressed on NK cells and a subset of T cells. Each KIR has an isoform with either a short (S) or long (L) cytoplasmic domain which transduces either an activating or inhibitory signal, respectively. The crossreactivity of the HP-MA4 antibody to KIR2DS3 and KIR2DS5 was published in 2013. Applications Reported: This HP-MA4 antibody has been reported for use in flow cytometric analysis. Applications Tested: This HP-MA4 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.125 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- HP-MA4
- Vial size
- 100 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references A comprehensive analysis of the binding of anti-KIR antibodies to activating KIRs.
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.
KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals.
Czaja K, Borer AS, Schmied L, Terszowski G, Stern M, Gonzalez A
Genes and immunity 2014 Jan;15(1):33-7
Genes and immunity 2014 Jan;15(1):33-7
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.
Tarek N, Le Luduec JB, Gallagher MM, Zheng J, Venstrom JM, Chamberlain E, Modak S, Heller G, Dupont B, Cheung NK, Hsu KC
The Journal of clinical investigation 2012 Sep;122(9):3260-70
The Journal of clinical investigation 2012 Sep;122(9):3260-70
KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals.
Foley B, De Santis D, Lathbury L, Christiansen F, Witt C
International immunology 2008 Apr;20(4):555-63
International immunology 2008 Apr;20(4):555-63
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of normal human peripheral blood cells with Anti-Human CD56 (NCAM) PerCP-eFluor® 710 (Product # 46-0567-42) and Mouse IgG2b K Isotype Control APC (Product # 17-4732-81) (left) or Anti-Human CD158a/h/g APC (right). Cells in the lymphocyte gate were used for analysis.